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Abstract Skeletal abnormalities are commonly seen in chil-
dren and adolescents with leukemia. The spectrum ranges
from mild pain to debilitating osteonecrosis (ON) and frac-
tures. In this review, we summarize the skeletal manifesta-
tions, provide an update on therapeutic strategies for preven-
tion and treatment, and discuss the most recent advances in
musculoskeletal research. Early recognition of skeletal abnor-
malities and strategies to optimize bone health are essential to
prevent long-term skeletal sequelae and diminished quality of
life observed in children and adolescents with leukemia.
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Introduction
Skeletal development in childhood is characterized by sex,
maturation, and race-specific increases in trabecular and cortical
bone mineral density (BMD) and cortical dimensions [1]. This
rapid accumulation of bone mass is dependent on the coordi-
nated actions of growth factors and sex steroids in the setting of
adequate biomechanical loading and nutrition. Thus, the grow-
ing skeleton is particularly vulnerable to the effects of child-
hood acute lymphoblastic leukemia (ALL) and hematopoietic
stem cell transplant (HSCT) therapies and complications that
suppress bone formation or promote bone resorption [2, 3].
Musculoskeletal abnormalities are well recognized in chil-
dren with ALL at diagnosis, during treatment, and persist as
long-term sequelae after treatment. The radiological abnor-
malities at diagnosis attributed to the leukemia process occur
in up to 70 % of children [4–6]. Osteotoxic chemotherapy,
steroid exposure, poor nutrition, low vitamin D, and poor
muscle mass contribute to the development or worsening of
bone pathology during therapy that may result in osteoporosis,
fracture, and ON. In children after HSCT and/or cranial irra-
diation, endocrine abnormalities further contribute to the bone
morbidity and altered quality of life.
Risk-directed therapy has substantially improved treatment
outcomes for pediatric ALL, with 5-year survival rates ap-
proximating 80 % [7]. Given success of this magnitude, it is
important to address the management and prevention of bone
toxicity. Our knowledge of bone pathogenesis in childhood
leukemia has advanced substantially over the past few de-
cades and is the focus of this review.
Skeletal Abnormalities at Leukemia Diagnosis
Radiographic abnormalities in childhood ALL have been
described in the literature for over 80 years. Metaphyseal
lucencies (ML) are the most common skeletal finding in most
series, occurring in 7.5 %–70 % [4, 6, 8–10]. Although well
recognized in children at the time of ALL diagnosis, ML are
not pathognomonic for leukemia. They occur most frequently
in the rapidly growing long bones, typically in the knees,
ankles, and wrists [6].
Other radiographic skeletal lesions observed at the onset of
leukemia include periosteal reaction (2 %–19 %) [6, 8, 9],
osteolytic lesions (19 %–38 %) [6, 9], osteopenia (low bone
mass on x-ray) (13 %–40 %) [8–10], and fractures (2 %–
10 %) [8, 9]. Periosteal reaction occurs following leukemic
infiltration between the periosteum and the cortex of the bone.
As new bone is formed, there is elevation of the periosteum.
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Osteolytic lesions are seen as focal lucencies throughout the
skeleton at the time of ALL diagnosis, occurring in the skull,
pelvis, long bones, and small bones of the hands and feet [9].
Osteopenia, a more generalized condition, is reported at diag-
nosis and can be seen in children presenting with pathological
fractures [8, 9].
The prevalence of non-vertebral fractures at ALL diagnosis
is mostly limited by reported findings in retrospective studies
and range from 3 % to 8 % [9, 11]. A single prospective study
with radiographs limited to hips, knees, and ankles showed a
prevalence of 10 % [8]. Similarly, vertebral fractures at the
time of ALL diagnosis are more common than the previously
reported fracture prevalence of 1.6 % based on a retrospective
review of chest radiographs [12]. As noted by Halton et al the
prevalence of severe vertebral compression fractures in chil-
dren with newly diagnosed ALL is as high as 16 % [13].
Although back pain is a recognized complaint in children with
vertebral fractures at ALL diagnosis, a significant proportion
of these fractures (45 %) are asymptomatic, despite identified
vertebral fractures on lateral spine imaging [13]. This is con-
sistent with reported data in postmenopausal women with
osteoporosis where vertebral compression fractures occur in
the absence of clinical symptoms [14]. Overall, there is no
identified relationship between vertebral fractures at ALL
diagnosis with leukocyte count, leukemia risk category, or
leukemia B or T subtype diagnosis [13, 15]. However, reduc-
tion in lumbar spine BMD Z-score at diagnosis is clearly
associated with increased odds for vertebral fracture (OR
1.8; 95 % CI 1.10–2.9; P<0.001) [13]. Bone fragility at the
time of ALL diagnosis has been linked to increased skeletal
resorption due to cytokine-mediated enhanced osteoclast ac-
tivity [16••, 17].
Bone and Mineral Homeostasis at Leukemia Diagnosis
Skeletal growth is unique to childhood and requires both
modeling and remodeling. Bone modeling results in a net gain
of bone volume, bone growth in length (through endochondral
bone formation), and in width (the latter, through periosteal
apposition) [18]. Remodeling occurs throughout life and
maintains the integrity of bone and mineral homeostasis.
Bone growth in length is not altered at leukemia diagnosis,
as absolute height in children with leukemia is not different
from healthy children [19]. However, bone density at leuke-
mia diagnosis is altered prior to initiating chemotherapy. At
diagnosis, serum markers of bone formation including
osteocalcin, type I collagen carboxy terminal propeptide, and
bone specific alkaline phosphatase are low [8, 20, 21]. Bone
resorption markers, urinary N-telopeptide and type I collagen
carboxy-terminal telopeptide, are normal or reduced in most
studies but not all [8, 20, 21]. Reduced bone formation
markers and low to normal resorption markers confirm a
low bone turnover state. Histomorphometric assessment at
diagnosis confirms the low bone turnover with reduced tra-
becular bone volume and reduced trabecular thickness [8, 22].
Defective mineralization of bone contributes to the bone
pathology seen at leukemia diagnosis. Several studies have
shown abnormally low levels of 1,25(OH)2D3, hypercalciuria,
low parathyroid hormone, and low to normal levels of calci-
um, magnesium and phosphate [8, 20]. Histomorphometric
biopsies are more sensitive than biochemical parameters for
d i a g no s i n g m i n e r a l i z a t i o n d e f e c t s [ 2 3 ] . Th e
histormorphometric biopsies of the iliac crest at diagnosis
show increased osteoid parameters suggestive of a delay in
matrix mineralization (osteomalacia) in a subset of children
[8]. Thus, the majority of children demonstrates altered bone
mineralization and reduced bone formation with increased
bone fragility prior to initiating osteotoxic therapy for the
treatment of leukemia.
Skeletal Abnormalities During Leukemia Therapy
ALL patients have increased incidence of fracture rates during
treatment compared with healthy controls [24]. The reported
incidence of nonpathologic fractures in ALL patients during
treatment varies from 12 % [9] to 39 % [25]. Similarly, Van
der Sluis et al noted a six-fold increase in fracture incidence in
ALL patients during maintenance phase of treatment com-
pared with healthy controls [26]. Furthermore, the incidence
of nontraumatic vertebral fractures in childrenwithALL1year
after initiation of chemotherapy is as high as 16 % (95 % CI
11 %–23 %), with 85 % of the incident vertebral fractures
occurring in previously normal vertebral bodies [16••].
Importantly, more than 50 % of children with incident verte-
bral fractures demonstrated vertebral fractures at baseline, and
the presence of at least one vertebral fracture at baseline was
highly associated with increased odds of sustaining at least
one incident vertebral fracture at 12 months (OR 7.30; 95 %
CI 2.30–23.14; P=0.001) [16••]. Children with identified
incident vertebral fractures at 12 months of ALL treatment
also demonstrate greater increases in spine BMD Z-scores
between 6 and 12 months of ALL therapy, suggesting that
the 12-month incident vertebral fractures may have occurred
earlier than the reported observation period and subsequently
followed by a degree of recovery manifesting as enhanced
BMD accrual [16••].
During ALL treatment, bone formation and resorption
markers are increased resulting in a decrease in total body
BMD (mean -0.68, SD 1.26) within the first six months of
treatment [25–27]. Longitudinal studies performed in children
at the time of ALL diagnosis and during first year of treatment
have revealed low lumbar spine BMD (-0.4 SD), [26, 28] with
prevalence ranging from 12 %–17 % in various cross-
sectional DXA-based studies [8, 26, 29]. Table 1 is a summary
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of studies examining BMD during ALL treatment [30].
Impaired BMD in childhood ALL is not only caused by the
disease itself but also further impacted by the disease treat-
ment. Corticosteroids, which play a critical role in ALL ther-
apy, directly affect bone, and negatively impact the skeleton
by altering the hormonal axis, intestinal calcium absorption,
and renal excretion of calcium [31••]. While corticosteroids
are the main culprit for skeletal toxicity in childhood ALL
[25], other chemotherapeutic agents such as methotrexate and
asparaginase additionally contribute to BMD deficits and
reduced bone mineralization [31••, 32]. These agents impair
osteoblast function, responsiveness and number, which sub-
sequently account for the suppression of bone formation and
contribute to the resultant osteopenia noted during and after
ALL treatment [33].
Impaired BMD in ALL involves both the trabecular and
cortical bone. Studies investigating bone geometry using pe-
ripheral quantitative computed tomography (QCT) in children
during ALL treatment demonstrate a reduction in trabecular
BMD in both weight bearing and nonweight bearing bones
[34]. Previous DXA studies at the time of leukemia diagnosis
have also demonstrated reduced lumbar spine BMD (LS), which
contains mostly trabecular bone, but with normal total body
BMD (TB) containing 80% cortical bone [25–28, 35, 36].While
BMDLS subsequently remains low during treatment, BMDTB
(cortical bone) declines rapidly during the initial phase of ALL
therapy. Both BMD values show improvement shortly after
cessation of ALL therapy but remain significantly lower com-
pared with healthy children [26, 37••]. A positive linear rela-
tionship is noted with lower BMDLS Z-scores at the time of
ALL diagnosis and during therapy. Children with low BMDLS
at diagnosis continue to demonstrate low BMDLS during the
later phases of therapy [29]. Lower weight is a notable deter-
minant of lower baseline BMDLS at the time of ALL diagnosis
[31••]. Older age at diagnosis is another independent risk factor
for a more rapid decline of BMDLS during ALL therapy,
reflecting the effects of more intensified chemotherapy [26,
31••]. Moreover, reduced BMDhas been demonstrated inmany
ALL survivors treated with chemotherapy alone and without
cranial radiation exposure, highlighting treatment factors other
than cranial radiation that negatively contribute to adverse
BMD effects during treatment [37••, 38].
Lower BMD at diagnosis is associatedwith higher prevalence
of subsequent bony fractures during ALL therapy [29]. More
importantly, pediatric patients with ALL demonstrate a higher
cumulative incidence of fracture rates during ALL therapy com-
pared with healthy, age-matched children [9, 16••, 25, 26, 39,
40]. Low lumbar spine BMD at the time of ALL diagnosis (–1.3
SDS) and during treatment (–1.6 SDS), rather than the treatment-
associated decline in BMD, is a strong determinant of markedly
increased fracture risk during the first 3 years after ALL diagno-
sis, with 59 % of patients demonstrating clinically significant
fractures (59 %) had lumbar spine BMD≤–2SD [31••]. Thus,
low lumbar spine BMD at diagnosis and during treatment should
be used to identify ALL patients at significant risk for bony
fractures and osteoporosis [31••].
Bone and Mineral Homeostasis During Leukemia
Treatment
Serum markers of bone formation are suppressed with admin-
istration of glucocorticoids and multi-agent chemotherapy
during ALL treatment [41]. Bone mineral accrual is adversely
affected by low serum 1, 25 (OH)2D3 and hypercalciuria [25]
Hypo- and hypermagnesemia associated with use of amino-
glycosides and glucocorticoids during ALL treatment affect
hydroxylation reactions necessary for production of 1, 25
(OH)2D3, and further contribute to mineralization defects
present during ALL therapy [25, 42, 43].
Osteopenia Prevention and Intervention
Physical activity combined with calcium and vitamin D sup-
plementation in healthy children enhances bone mass accrual
[44, 45]. Thus, promoting physical activity and exercise dur-
ing and after ALL treatment, particularly given the marked
reduced physical activity in some ALL survivors, may ame-
liorate bone mass acquisition during treatment. Additional
nutritional supplementation with calcium and vitamin D may
further augment the bone response to physical activity.
However, Kaste SC et al reported no added benefit of chole-
calciferol and calcium supplementation to nutritional counsel-
ing for improving lumbar spine BMD among adolescent and
young adult survivors of ALL [46]. Anecdotal evidence exists
for the use of bisphosphonates to improve BMD or treat bone
fragility at diagnosis or during treatment of childhood ALL
[47]. Given the small number of reported subjects and lack of
randomized, controlled study design, the wider applicability
of this approach deserves marked caution particularly as the
effects of bisphosphonates on the leukemic disease process
and treatment remain largely unknown. A key clinical ques-
tion unanswered to date arising from the observation that
reductions in BMD and prevalent vertebral fractures at diag-
nosis predict future fractures [16••, 48] is whether children
with ALL and vertebral fractures early in the course of ALL
treatment should be treated with bisphosphonates to prevent
future fractures. To date there have been no randomized,
placebo-controlled trials in pediatric ALL to provide adequate
safety and efficacy data to justify this approach as standard of
care. Thus, the use of bisphosphonates, at this time, remains
limited to children with severe, symptomatic bone morbidity
administered only on compassionate grounds [16••].
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Skeletal Recovery After Leukemia Therapy
To date, fractures among long-term childhood cancer survi-
vors remain largely uncharacterized. While prior studies re-
port fractures during ALL therapy or within the first few years
of treatment cessation, it is unclear whether the alterations to
bone metabolism during ALL therapy also impact post-
therapy risk of fractures. Furthermore, most of these studies
are limited by small sample size and, thus, unable to consider
additional factors such as survivor demographics and life style
on future fracture risk.
Nysom et al reported a fracture prevalence of 55 % in ALL
survivors, median of 7.6 years (range 1.6–18.3 years) from
completion of therapy. In this small, cross-sectional study,
fracturesweremore common in younger participants (<20 years
old) compared with controls, with no fractures noted among
survivors within the oldest age group (>29 years). Furthermore,
none were spinal compression fractures [49]. In a subsequent
retrospective study, the 5-year cumulative incidence of fractures
in ALL survivors was 28±3 %, with 85 % of fractures occur-
ring during maintenance phase or shortly after ALL treatment
cessation. The median time to fracture was 15 months from
diagnosis (interquartile range 10–24months) [50], and majority
of fractures occurred in long bones with only 4 reported verte-
bral fractures. The cumulative incidence was higher in males
(37±5 %) and patients ≥9 years of age (46±8 %), suggesting
increased fracture rates in adolescent males after ALL treat-
ment, possibly from participation in organized sports or risk-
taking behaviors [50]. On the other hand, in the largest cross-
sectional study to date, with amedian of 22.7 years of follow-up
from cancer diagnosis, the childhood cancer survivor study
reported a comparable fracture prevalence ratio between female
ALL survivors and their siblings (0.99; CI 95 % 0.88–1.12; P=
0.87), while among males, the prevalence ratio of fractures was
lower among survivors relative to the sibling control group
(0.91; 95 % CI 0.83–1.00; P=0.05) [51••]. A recognized lim-
itation of this study is use of self-report questionnaires to collect
information on fracture occurrence and health-related informa-
tion among survivors of childhood cancer and their siblings. In
addition, interpreting these results requires caution as majority
of ALL survivors have yet to reach an age where the underlying
population risk of fracture increases substantially. Likewise, the
frequency of permanent vertebral deformity arising from prior
vertebral fractures and its long-term sequelae in ALL survivors
Table 1 Summary of DXA studies of bone mineral density (BMD) during treatment for childhood acute lymphoblastic leukemia (ALL)
Study design N Cranial XRT Comments
Halton et al. [25] Longitudinal
2 y tx
40 Y ↓ lumbar spine BMD from baseline in 47 % of children,
↓ lumbar spine BMC from baseline in 64 % of children.
Compared w/ the status at dx, Z scores for BMD and BMC
were not statistically significant throughout the 2 y of therapy.
Henderson et al. [28] Longitudinal
One y during tx or post-tx
37 a Y ↓ of≥0.5 SD femoral BMD in 23 % of patients, ↓ lumbar spine
BMD in 27 % of patients. Mean change in lumbar spine BMD z
score –0.21±0.14 and proximal femur –0.07±0.12.
Arikoski et al.[27] Longitudinal
dx to 6 mo of tx
46 a Y ↓ (-2.1 %) lumbar spine BMAD from baseline, ↓ (–8.5 %) femoral
BMAD from baseline,
↓ (-9.9 %) femoral BMD from baseline, ↓ (–0.7 SD) femoral BMD,
↓ (–0.7 SD) femoral BMAD,↔ BMD lumbar spine.
Arikoski et al. [20] Longitudinal
dx to 1 y tx
28 a Y ↓ (–10.1 %) femoral BMAD from baseline, ↓ (–11.3 %) femoral
BMD from baseline over first 12 mo after diagnosis.
Boot et al. [35] Longitudinal
dx, 6 mo, 1 and 2 y on tx,
and 1 y post-tx
32 N ↓ (-1.1 SD) whole body BMD between dx and within first y of
treatment,↔ lumbar spine BMD during the first 6 mo
after diagnosis.
van der Sluis et al. [26] Longitudinal
dx, during tx, and 1 y after tx
61 N ↓ (-0.68 SD) whole body BMD, ↓ (-0.65 SD) lumbar spine BMD,
↔ lumbar spine BMAD in the first 32 wk of treatment.
Davies et al. [36] Longitudinal
dx and 2 y tx
14 N ↓ femoral neck % BMC (82 %), ↓ femoral trochanter % BMC
(72 %), ↓ lumbar spine % BMC (89 %),↔ whole body % BMC etc.
Alos et al. [16••] Longitudinal
dx and 12 mo tx
155 N Δ lumbar spine BMD Z-score from baseline to 6 mo - children w/o
incident vertebral fractures at 12 mo: mean=0.1, SD 0.8;
children w/ incident vertebral fractures at 12 mo: mean=0.1, SD=0.9.
Δ lumbar spine BMD Z-score from 6 to 12 mo: w/o fractures:
mean=0.0, SD=0.6, w/ fractures: mean=0.3, SD=0.5.
Δ lumbar spine BMD Z-score from baseline to 12 mo: w/o fractures:
mean=0.0, SD=0.8; w/ fractures: mean=0.3, SD=1.1.
a Cohort included other childhood malignancies; ↑, increase; ↓, decrease;↔, no change
% BMC% of control bone mineral content, BMAD bone mineral apparent density, dx ALL diagnosis, mo months, tx ALL treatment
Adapted from Davies et al [30]
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remain unknown. Therefore, future longitudinal studies in long-
term ALL survivors are critical to better delineate the effects of
chemotherapy and radiation on bone health of aging survivors.
After completion of ALL treatment with chemotherapy
alone, no significant long-term decreases in BMD are present
in longitudinal follow-up studies [37••, 52]. Importantly, low
trabecular BMD improves significantly after completion of
ALL therapy. On the other hand, early increases in cortical
dimensions are associated with a decline in cortical BMD;
however, over time, ALL survivors demonstrate stable corti-
cal dimensions with an increase in cortical BMD, reflecting
the time necessary to mineralize newly formed bone [37••].
On the other hand, patients treated with cranial or spine
radiation continue to demonstrate significantly reduced total
body and lumbar spine BMD long after completion of ALL
therapy [53–55], with high dosage (≥24 Gy) of cranial or
craniospinal radiation the strongest identified risk factor for
persistently low BMD (Z-score≤-1) during young adulthood
[56]. Defects in the hypothalamic-pituitary axis leading to
abnormalities in growth hormone production, direct radiation
effects on developing bone, as well as inadequate gonadal
function are probable causes leading to this prolonged distur-
bance of bone metabolism. Majority of BMD differences in
adult ALL survivors compared with healthy controls stem
from reduced adult height in ALL survivors after cranial
radiation, with the DXA-derived values no longer significant-
ly abnormal once they are adjusted for the short stature [55].
However, spine QCT measures of trabecular BMD in ALL
survivors (median 31 years old) treated with cranial or
craniospinal radiation demonstrate a 5.7 % prevalence of
BMD Z-score≤–2, suggesting long-standing effects of subop-
timal BMD in this select group of patients [56]. Additional
potential identified risk factors contributing to low BMD in
adult ALL survivors include inadequately treated
hypogonadism, vitamin D deficiency, low physical activity,
and inadequate growth hormone production. These risk fac-
tors can provide guidance in identifying and targeting specific
adult ALL survivors at marked risk for skeletal complications
during adulthood. However, the majority of younger children
treated with chemotherapy alone recover from BMD deficits
over time with no lasting deficits into young adulthood [52,
56]. Given that ALL is the most common malignancy of
childhood, these findings are reassuring and highlight that
the most significant skeletal impact of ALL is at the time of
diagnosis followed by active phase of treatment with substan-
tial recovery following completion of therapy.
Skeletal Abnormalities after Hematopoietic Stem Cell
Transplantation
The pathogenesis of bone deficits in pediatric HSCT recipi-
ents is multifactorial. HSCT myeloablative regimens can
directly damage the recipient’s osteoprogenitor cells within
the bone marrow, negatively affecting bone formation [57].
Survivors of allogeneic HSCT demonstrate additional risk
factors for poor bone health, including malnutrition [42],
reduced muscle strength [58], chemotherapy [41], total body
irradiation, immune suppressive therapies, and sex hormone
deficiencies [59]. Graft Vs Host Disease (GVHD) and dys-
regulation of the immune system serve as additional threats to
bone health, due to osteoclast activation, and reduced osteo-
blast number as well as function [60]. These risk factors have
lasting effects that persist long after HSCT treatment [61•].
The true fracture incidence after childhood HSCT is not
known, and only a few cross-sectional studies to date have
actually examined the prevalence of fracture rates in long-term
pediatric HSCT recipients [61•, 62, 63]. While an increased
prevalence of fracture rates is not identified in long-term
survivors of childhood HSCT, these few studies are limited
by cross-sectional design, small sample size, and the use of
self-report for identifying fractures. Therefore, the true inci-
dence of clinically asymptomatic fractures remains poorly
delineated in this increasing population at significant risk for
inadequate bone accrual and metabolism.
DXA-based studies in children and adults within the first
year following allogeneic HSCT have demonstrated substan-
tial bone deficits, in conjunction with elevated markers of
bone resorption, and low markers of bone formation
[64–66]. However, there are only a few studies specifically
assessing BMD in survivors of pediatric allogeneic HSCT, all
with variable findings (Table 2) [64, 67–70]. In one of the
earliest studies, Bhatia et al reported DXA total body BMD
deficits (median Z-score -0.5) in a small sample of 10 pediatric
patients, ages 3–18 years, and a median of 2 years following
allogeneic HSCT. Unfortunately, this study was limited by
lack of data on the effect of growth failure on DXA BMD Z-
scores relative to age [71]. In contrast, Nysom and colleagues
reported no difference in height-adjusted DXA whole-body
BMD and bone mineral content in 25 survivors of allogeneic
HSCT 4–13 years after HSCTcompared with healthy controls
[68]. However, as noted previously, DXA methods adjusting
for BMD Z-scores without consideration of age results in an
underestimation of bone deficits, which likely accounts for the
absence of bone deficits reported by Nysom and colleagues in
this study [68, 71].
As DXA is a two-dimensional technique that combines
trabecular and cortical bone mass within a projected bone
area, it does not allow for discrete measures of trabecular
and cortical volumetric BMD or cortical dimensions. On the
other hand, QCT is a three-dimensional technique, which
distinguishes between cortical and trabecular bone. To date,
only two studies utilize QCT to examine trabecular BMD and
cortical dimensions following HSCT [61•, 67]. In a study by
Kaste and colleagues, significant deficits were reported in
QCT measures of spine trabecular volumetric BMD in 48
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allogeneic HSCT survivors (median Z-score -0.88) a median
of 5 years after HSCT. These deficits were not associated with
gender, age at HSCT, interval since HSCT, conditioning reg-
imen, or endocrine dysfunction in survivors [67].
Subsequently, Mostoufi-Moab et al reported substantial
growth failure (median Z-score -1.21), low trabecular volu-
metric BMD (median Z-score -1.05), smaller cortical dimen-
sions (median section modulus Z-score -0.63 even after ad-
justment for shorter tibia length), and marked cachexia (me-
dian muscle cross-sectional area Z-score –1.01) in 50 long-
term survivors of allogeneic HSCT (range 3–16 years since
HSCT) using peripheral QCT compared with a large healthy
reference population [61•]. The magnitude of these deficits
exceeded those observed in children with active Crohn’s
disease [72], juvenile rheumatoid arthritis [73], and chronic
kidney disease [74], highlighting the lasting impact of
allogeneic HSCT and its therapies. Importantly, the vast
majority of the HSCT recipients in this study had not been
treated with corticosteroids or immune suppressive medica-
tions for many years. Furthermore, the study delineated
discrete associations between TBI, growth hormone defi-
ciency (GHD), and trabecular and cortical deficits despite
appropriate hormone replacement in subjects with a diag-
nosis of endocrinopathy (median trabecular BMD Z-score
after TBI -1.30 vs -0.49 without TBI). Allogeneic HSCT
survivors also demonstrated significant pubertal delay as
expected from treatment-related toxic gonadal effects.
Thus, treatment-associated GHD and hypogonadism further
contribute to compromised skeletal acquisition in pediatric
allogeneic HSCT survivors. While both studies were limited
by cross-sectional design, they demonstrate striking bone
deficits years after HSCT and completion of therapy. Future
longitudinal studies are necessary to determine if these
deficits progress or recover over time and to identify asso-
ciations with fracture.
Osteonecrosis
ON is a serious and debilitating complication of ALL and its
treatment. The etiology of developing ON in ALL is complex
and attributed, at least in part, to the use of high dose cortico-
steroids [75]. A myriad of pathophysiologic mechanisms have
been postulated including altered bone and lipid metabolism
and thrombophilia. The final common pathway in the devel-
opment of ON is compromised blood flow resulting in infarc-
tion and necrosis of the bone [76]. ON results from: (1) direct
suppression of osteoblasts and apoptosis of osteocytes, (2)
stimulation of intramedullary lipocyte proliferation and hyper-
trophy within the bone marrow, resulting in reduced blood
flow, and (3) further stasis and ischemia due to impact on
vascular endothelial and smooth muscle cells [77–79].
Over the past 2 decades, ON has become the focus of
numerous studies to determine the extent, onset, cause, and
outcome of this disorder. The prevalence has been reported in
several retrospective and prospective series from cooperative
leukemia clinical trial groups as well as large single institu-
tions (Table 3). Prevalence and incidence rates vary widely
due to the study population [high risk patients (HR) vs com-
bined HR and standard risk (SR) patients], retrospective vs
prospective, symptomatic vs asymptomatic, and by method of
detection. Cumulative incidence of symptomatic ON at the
end of leukemia therapy occurs in 0.9[80] to 17.6 % [81••]
while asymptomatic ON occurs in up to 53.9 % [81••]. In
symptomatic children, the clinical course is often multi-
articular and bilateral with the hips and knees most commonly
affected [75, 82]. Recent studies using whole body MRI
assessing the entire skeleton have shown widespread multifo-
cal lesions affecting upper and lower extremity joints (hips,
knees, shoulders), long bones, and 10 % of lesions involved
the small bones of the hands and feet [83]. The natural history
of development and progression of ON in pediatric leukemia
Table 2 Summary of DXA studies of low bone mineral density (BMD) after childhood allogeneic HSCT






DXA Z-score P value b Height Z-
score
Total body BMD Lumbar spine
BMD
Bhatia et al. [64] 10 Cross-sectional 5 (3–18) c 12 (4–22) c 2 (1–10) –0.5 (–2.0 to 1.0) c 0.05
Nysom et al. [68] 25 Cross-sectional 11 (6–18) c 18 (11–27) c 7 (4–13) –0.5c –0.5 c 0.08; 0.54
Petryk et al. [69] 21 Longitudinal 10 (5–18) d 10 (5–18) d ≤ 1 ƒ–0.9 (–2.9 to 1.1) d 0.022
Perkins et al. [70] 17 Cross-sectional 13 (4–24) d 13 (4–24) d 12 (3–22) d –0.3 (–2.4 to 2.0) d –1.8
HSCT hematopoietic stem cell transplant
a Follow-up y since HSCT
bP value compared with healthy controls
cMedian (range)
dMean (range)
ƒRepresents value at 1 year follow-up time point since HSCTcompared with baseline; authors stated no change in lumbar spine BMD after adjusting for
1 year change in height SD but actual results not reported.
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are poorly understood. Predictors associated with joint col-
lapse and need for arthroplasty include older age at diagnosis,
pain, area of ON >30 % and lesions close to the articular
surface [84, 85]. The clinical significance of asymptomatic
ON in children is unclear as the lesions may resolve, remain
stable or progress [86, 87••].
The onset of ON is highly variable with several case reports
of ON detected at diagnosis [88]. In most series, the majority
of children present within the first 2 years from diagnosis [75,
81••, 82, 89–91]. Magnetic resonance imaging (MRI) is a
sensitive tool for detecting ON at earlier stages and in asymp-
tomatic locations [81••]. Research from St. Jude’s Hospital
using a prospective MRI surveillance study of ON identified
all symptomatic patients within the first year of ALL diagno-
sis. The cumulative incidence at one year was 14.6 % for
grade 2–4 ON and 35.4 % for grade 1 ON. The presence of
ON at initial MRI screening performed during the first 6–
8 months of ALL therapy was the most robust predictor of
subsequent ON progression [81••]. Patients with grade 1 ON
at first MRI screening were more likely to develop symptom-
atic grade 2–4 ON (26 %) compared with patients initially
negative for ON (14 %) [81••].
In most series, age >10 years [50, 75, 81••, 82, 89, 91–98],
female sex [80, 82, 87••, 89, 97], and Caucasian race [82, 92]
are identified risk factors for developing ON. Increased BMI
[99] is another recognized risk factor in some but not all
studies [93]. Cumulative exposure to steroids is a key factor
in the development of ON, and corticosteroids are the essential
component of childhood ALL therapy. Improvements in event
free survival have been attributed to the more potent antileu-
kemic effect of dexamethasone compared with prednisone
[80, 95]. However, the frequency of ON is greater with ALL
treatment regimens using dexamethasone [82, 90, 95]. Burger
et al reported on the prednisone equivalent dose from three
leukemia cooperative group trials and showed that the higher
incidence of ON was associated with a higher total steroid
dose [75]. Mattano reported that ALL patients in the HR
group receiving two dexamethasone pulses exhibited a 1.4-
fold higher increase in symptomatic ON than those who
received a single dexamethasone pulse [82]. Dexamethasone
dosing schedule may also be a factor in the development of
ON. Alternate-week dexamethasone dosing has shown a low-
er incidence of ON (11.8 % vs 23.2 %) compared with
continuous dexamethasone dosing [91].
Recent studies have reported predictive biomarkers identi-
fying patients at genetic risk of developing ON. Single nucle-
otide polymorphism (SNPs) arrays have identified multiple
candidate genes including PAI-1(SERPINE 1) [100], VDR
[92], and CYP3A4 [101], with conflicting results [100, 102].
More recently a locus on chromosome 2 encoding for ACP1
and SH3YL1(which regulates lipid levels and osteoblast dif-
ferentiation) have been identified as a biomarker for symp-
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association with a phenotype of higher cholesterol and lower
albumin, independent risk factors for ON [81••]. However,
thrombophilia testing including Factor V Leiden,
P r o t h r o m b i n 2 0 2 1 0 G→ A a n d m e t h y l e n e
tetrahydrofolatereductase (MTHFR,677C—T) were not asso-
ciated with ON [103].
Similarly, pediatric HSCT recipients are at high risk for the
development of ONwith prevalence as high as 44% in HSCT
survivors screened by MRI [67, 104]. However, the true
prevalence of ON is unknown, as the majority of HSCT
recipients do not undergo prospective screening assessment
with MRI, which is a more sensitive method for detecting ON
[105]. The reported median interval for development of ON in
pediatric HSCT recipients is 11 months after HSCT[106] with
the earliest time point from 1 to 6 months after the onset of
glucocorticoid therapy for the treatment of GVHD [107, 108].
Patients typically present with vague, diffuse bone pain with
majority manifesting ON in 2 or more joints [107]. Once
again, pathogenesis is multifactorial and corticosteroids are
the strongest risk factor for ON with both the cumulative dose
as well as the duration of treatment playing a role [76, 109].
Higher incidence of ON is present in TBI-based conditioning
regimens likely due to radiation-induced micro-vascular dam-
age [77]. The risk of ON increases with GVHD, possibly from
GVHD-related increased risks for microangiopathy [78].
Notable overlap exists between risk factors for low BMD
and ON following pediatric HSCT, with both conditions
coexisting in pediatric HSCT survivors as they share similar
pathogenic pathways and likely have additive effects [85].
Thus, the impaired osteoblast activity after HSCTcan contrib-
ute to reduced BMD and the reduced number of osteoblasts
can in turn adversely affect the regenerative potential of the
osteogenic compartment over the course of ON after pediatric
HSCT [108]. Future, prospective studies are necessary to not
only identify the exact incidence and timing of ON occurrence
after HSCT, but also discern effective and safe pharmacologic
interventions in ON prevention as well as treatment in pedi-
atric HSCT survivors.
ON Prevention and Treatment
Despite improved survival of childhood ALL, treatment-
related skeletal complications such as ON significantly con-
tribute to short- and long-term disability in many survivors of
pediatric hematologic malignancies and HSCT [84]. Given
the variable natural history of ON, treatment decisions have
been equally difficult with notable lack of established stan-
dardized regimens. Current treatment options for ON include
analgesia, [84] limited weight bearing, physical therapy, and
surgical procedures including core decompression [110] as
well as joint replacement [111]. Other newer surgical tech-
niques include the use of vascularized bone grafts [112], and
the combination of core decompression with the insertion of
human bone morphogenetic protein [113]. While surgery still
remains the conventional approach, there is concern about the
use of surgical interventions in growing pediatric patients with
open physes [82, 114].
Additional alternative treatments have included external
stimulation/capacitance coupling [115, 116] as well as the
use of hyperbaric oxygen, all without any established clear
benefits [117]. A number of medical therapies have also been
undertakenwith variable and inconsistent results including the
use of calcium channel blockers (nifedipine), prostaglandin
infusions, low molecular weight heparin, and statins
[118–121]. These pharmacologic agents predominantly ame-
liorate the regulation of blood supply targeting local ischemia
[122] or lipocyte proliferation [120]. More recently, several
studies with small number of adult and pediatric subjects have
reported the use of bisphosphonates for the treatment of ON
[123–126]. The rationale for the use of bisphosphonates stems
from the prevention of osteoclast bone resorption during the
revascularization and uncoupled bone remodeling phase in the
ON bone, and, thus, preserving bone shape; [84, 127] how-
ever, the data on the clinical and radiological outcome of
children with chemotherapy-associated ON treated with
bisphosphonates remains limited [84, 128•, 129].
While treatment with bisphosphonates contributes to pain
improvement with a reduced requirement in oral analgesia,
their use has failed to demonstrate the prevention, destruction,
and subsequent collapse in hip joints, which is the most
affected of weight-bearing joints [84]. This limited effective-
ness of bisphosphonates in treatment of hip ON might reflect
inadequate drug distribution to areas of necrotic bone [84]
However, limited data in one study using zoledronic acid in a
small group of patients suggested slowed progression of joint
destruction predominantly in knee joints [84]. Unfortunately,
children and adolescents with advanced ON joint involvement
at the end of cancer treatment are more likely to develop early
osteoarthritis and require joint replacement early in adult life,
with the relative risk of major joint replacement in long-term
survivors of childhood cancer compared with siblings report-
ed at 54 % (95 % CI 7.6–38.6) [130]. Thus, given that
treatment with bisphosphonates in cancer survivors remains
safe without any significant side effects, future novel treat-
ment approaches and strategies, such as prophylactic admin-
istration of bisphosphonates, might prove more effective in
reduction of the frequency and severity of ON during treat-
ment for childhood hematologic malignancies or HSCT [131].
Conclusions
In summary, the growing skeleton is vulnerable to the leukemic
process and its osteotoxic therapy. Early recognition and inter-
vention strategies to optimize bone health are essential to
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prevent long-term sequelae from osteopenia, fractures and
osteonecrosis observed in children and adolescents with leuke-
mia. DXA assessments of BMD at the time of leukemia diag-
nosis and the presence of vertebral compression fractures
should be used to predict bone health during treatment.
Following cessation of leukemia treatment or HSCT, survivors
require continued surveillance for skeletal morbidities into late
adulthood with specific attention to bone health including op-
timization of nutrition, mobility, and exercise. Future studies are
necessary to examine the impact of interventions such as bis-
phosphonate therapy, exercise, and nutritional supplements
both during and following leukemia treatment.
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